Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Replimune GroupHAM:7R8 -0.73%19 5-Day RSI is 72.10 as of Aug. 13, 2026. GuruFocus rates HAM:7R8 with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, Replimune Group ranks worse than 89.82% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-08-13), Replimune Group's 5-Day RSI is 72.10.
The industry rank for Replimune Group's 5-Day RSI or its related term are showing as below:
HAM:7R8's 5-Day RSI is ranked worse than 89.82% of 1415
companies
in the Biotechnology industry
Industry Median: 57.89
vs HAM:7R8: 72.10
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Replimune Group 5-Day RSI Related Terms
HAM:7R8 vs ANNX, SLDB, ABUS: 5-Day RSI Comparison
For the Biotechnology subindustry, Replimune Group's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group 5-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Replimune Group's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (HAM:7R8) has a 5-Day RSI of 72.10 as of Aug. 13, 2026. According to the industry distribution chart, Replimune Group ranks #1271 out of 1415 companies in the Biotechnology industry, placing it in the top 89.8%.
Is Replimune Group's 5-Day RSI too high?
Replimune Group's current 5-Day RSI is 72.10. The Biotechnology industry median 5-Day RSI is 57.89. Replimune Group's value of 72.10 is 24.5% above this industry median. Based on the distribution chart, Replimune Group ranks #1271 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's 5-Day RSI compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #1271 out of 1415 companies for 5-Day RSI. This places Replimune Group in the lower half of its industry. The industry median 5-Day RSI is 57.89. Replimune Group's value of 72.10 is 24.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 57.89, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Replimune Group's current 5-Day RSI of 72.10 is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 57.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current 5-Day RSI is 72.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (HAM:7R8) has a current 5-Day RSI of 72.10. The current 5-Day RSI is 72.10 and 24.5% above the Biotechnology industry median of 57.89. Replimune Group's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Replimune Group (HAM:7R8), the current 5-Day RSI is 72.10 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
19GF Score
Get the complete analysis for HAM:7R8
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:7R8 has been successfully added to your 
